Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA.

Authors :: Martin T
Richardson PG
Facon T
Moreau P
Perrot A
Spicka I
Bisht K
Inchauspé M
Casca F
Macé S
Van de Velde H
Suzuki K
Source :: Haematologica [Haematologica] 2022 Oct 01; Vol. 107 (10), pp. 2485-2491. Date of Electronic Publication: 2022 Oct 01.
Publication Year :: 2022

Subjects :: Antibodies, Monoclonal, Humanized therapeutic use
Antineoplastic Combined Chemotherapy Protocols
Dexamethasone therapeutic use
Humans
Neoplasm Recurrence, Local chemically induced
Neoplasm Recurrence, Local drug therapy
Thalidomide therapeutic use
Multiple Myeloma drug therapy
Neoplasms, Plasma Cell

Full Text Access

Tools